Donisi Health: Funding, Investors & Team (Sep 2026)

Donisi Health (Donisi), formally ContinUse Biometrics Ltd., is a global company at the forefront of cardiac health monitoring. Designed to enable personalized predictive cardiopulmonary health insights, Donisi’s innovative easy-to-use contact-free solution detects multiple bio-parameters simultaneously. Backed by 26 granted patents, Donisi’s system is the only clinically validated contact-free device that can identify pulmonary congestion & more. Donisi’s award-winning health sensing system is cleared by the U.S. Food and Drug Administration (FDA) via the de novo pathway. In other words, we are the only company in the world to provide health indications over light waves at a medical level (acknowledged by FDA). In addition to the de novo clearance, the ingenuity of Donisi’s groundbreaking system was recently recognized via the publication of their clinical validation study in the Journal of Medical Engineering & Technology and winning first place in the MEDinISRAEL OpenMED Innovation Competition. Extensive clinical results demonstrate Donisi’s technology maintains medical-grade accuracy for people with different medical and physical conditions (physique, skin tone, etc.) without needing to remove clothing or connect the patient to wires or patches.

Donisi Health has raised $200k across 1 round on record. The most recent is a Grant of $200k announced in Dec 2021.

Donisi Health's most recent funding round on record is a Grant of $200k, announced in Dec 2021.

Yair Brosh is listed as CEO at Donisi Health.

Donisi Health is based in Tel Aviv, Israel.

Donisi Health is in the 11-50 employee band.

Donisi Health's latest round of $200k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.